XML 38 R22.htm IDEA: XBRL DOCUMENT
v3.20.2

REVENUES - Company's disaggregation of revenues (Details) - USD ($) $ in Thousands |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Mar. 16, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Revenues |  | $ 10,967 | $ 12,247 | $ 32,613 | $ 22,686
Non refundable payments not yet recognized to revenues | $ 1,000 |  |  |  |
Pfizer [Member] |  |  |  |  |
Revenues |  |  |  | 2,679 | 2,735
Brazil [Member] |  |  |  |  |
Revenues |  |  |  | 6,000 | 4,225
Chiesi US Agreement [Member] |  |  |  |  |
Revenue recognized due to change in estimate of total costs expected to be incurred |  |  |  | 6,700 |
Goods [Member] |  |  |  |  |
Revenues |  | 3,648 | 3,430 | 8,679 | 6,960
License and R&D Services [Member] |  |  |  |  |
Revenues |  | $ 7,319 | $ 8,817 | $ 23,934 | $ 15,726

X
- Definition The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured. + References No definition available. + Details
Name: | plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of non refundable payment not yet recognized to revenues. + References No definition available. + Details
Name: | plx_NonRefundablePayment
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |